Who Is Funding RCM Automation in 2026? Nine Rounds, $372 Million, and a Growth-Stage Tilt
Our tally of 2026's disclosed revenue-cycle rounds shows about 73% of the dollars came from growth-stage funds, while early-stage VCs wrote the smaller first checks.
Revenue cycle management used to be the part of health tech investors skipped. In 2026 it is where some of the biggest checks are landing. Fierce Healthcare opened its coverage of Candid Health's July round by saying venture funding for AI-powered RCM startups "is surging." We tallied the disclosed 2026 rounds in and around the provider revenue cycle to see who is writing the checks.
The tally
Here are the nine disclosed rounds we could confirm from company or investor announcements between February and November 2026:
| Date (2026) | Company | Round | Lead investor |
|---|---|---|---|
| Feb 3 | Alaffia Health | $55M Series B | Transformation Capital |
| Mar 11 | Translucent | $27M Series A | GV |
| Mar 25 | Adonis | $40M Series C | Quadrille Capital |
| Apr 16 | Joyful Health | $17M Series A | CRV |
| Apr 22 | Amperos Health | $16M Series A | Bessemer Venture Partners |
| May 13 | Anomaly | $17M | Sound Ventures |
| Jul 22 | Candid Health | $120M Series D | Sixth Street Growth |
| Aug 26 | Arintra | $25M Series B | Define Ventures |
| Nov 10 | Charta Health | $55M Series B | Insight Partners |
Together that is $372 million. It is not a complete census. Alaffia sells to health plans rather than providers, Translucent is hospital finance software rather than claims work, and undisclosed deals such as CVS Health Ventures' investment in Fathom are left out of the math.
The pattern: growth money takes the big checks
Sorting the leads by our own classification, four growth-stage firms (Sixth Street Growth, Insight, Quadrille and Transformation Capital) led rounds totaling $270 million, or about 73% of the dollars. Five venture funds (GV, CRV, Bessemer, Sound and Define) led rounds totaling $102 million. The largest early-stage lead was GV's $27 million.
That split makes sense for where the companies are. Candid says it has raised more than $219 million to date and reports 190% year-over-year annual contracted run-rate growth. Adonis says it grew revenue more than 4x in 2025 with net retention above 130%. Those are company-reported figures, but they explain why growth investors are comfortable underwriting nine-figure rounds.
Who comes back
Repeat checks show conviction:
- Candid: Oak HC/FT led the $52.5M Series C in February 2025 and participated again in the Series D, per Fierce.
- Charta: Bain Capital Ventures led the $22M Series A in July 2025. Insight's Series B announcement lists BCV among the existing investors who joined. MobiHealthNews counts it as Charta's third round in under two years, with $85 million raised in total.
- Adonis: General Catalyst and Bling Capital continued to back it in the Series C.
Where the dollars point
Most of these companies are not selling dashboards. They are selling to take over work. Bessemer says it is leading Amperos because it believes AI agents will take denial workflows over entirely rather than speed up pieces of them. Define describes Arintra as autonomous coding that it says codes 86% of claims without human intervention. Insight's pitch for Charta is that the real opportunity is upstream, getting the chart right before a claim goes out.
Hospital demand is there, though execution is slower than the funding. An HFMA and AKASA survey of 519 finance leaders found that 80% of health systems are exploring, piloting or implementing gen AI for RCM, up 38% in under two years, but cost and integration remain barriers. AKASA commissioned the survey and also sells in this market.
What we're watching
- Whether growth rounds end in exits. Private-equity platforms such as New Mountain's Smarter Technologies have been buying and combining RCM assets since 2025. Whether the 2026 crop becomes their targets is our open question, not a reported fact.
- Who funds the next layer. Payer-side claims AI (Alaffia) and payer-intelligence (Anomaly) are drawing money alongside provider-side tools.
- Proof beyond press releases. Almost every performance figure above comes from the company or its investor, so independent customer evidence will separate the winners.
Methodology: Rounds come from company, investor and trade-press announcements surfaced in the Clinical Terminal signal feed and verified against the linked sources. Lead-investor classification (growth vs. venture) is the Clinical Terminal News Desk's own. Performance metrics are company-reported unless noted.